The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on 4 June, with more than 2,500 abstract presentations representing cutt 28 May 2021
The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency’s Priority Review scheme, with a dec 27 May 2021
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai’s Junshi Biosciences (HKEX: 1877) to shine. 25 May 2021
While UK-based drugmaker AstraZeneca has mostly made headlines for its development of a coronavirus vaccine, the firm’s work in oncology is potentially of great 25 May 2021
Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at 25 May 2021
In a Special Report, Mircea Cubillos, Regional Commercial Strategy Leader, Haematology, Janssen EMEA, reflects on the recent ASCO and EHA congresses. And despit 24 June 2020
Regeneron and Sanofi have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell c 1 June 2020
Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically meaningful 1 June 2020
Swiss pharma major Novartis (NOVN: VCX) has announced a new exploratory subgroup analysis from the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented 27 May 2020
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next maj 17 June 2019
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
The headline-grabbing results on AMG 510, the first KRASG12C inhibitor to reach the clinical stage, were not the only data to be shared by US biotech Amgen on i 5 June 2019
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.